Numerous clinical trials have shown the safety and therapeutic efficacy of IFN-α2 or IFN-β administration to COVID-19 patients [55], although treatment with IFN-α2 or IFN-β would be less effective for patients with auto-abs to type I IFNs than patients without auto-abs. The gene discussed is IFNA2; the disease is COVID-19.